Literature DB >> 19493018

Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.

C E Walsh1, L A Valentino.   

Abstract

The emergence of a population of relatively healthy adults with severe haemophilia A presents a unique challenge for haemophilia care in the 21st century. Understanding how best to continue, restart, initiate or modify prophylaxis in younger and older adult patients is essential to optimizing their care. To elucidate practice and outcome data, a survey was sent to 23 US hemophilia treatment centers (HTCs); 10 centers responded, providing data concerning up to 145 adults (mean age of 34 years). Forty-eight patients (33%) were on regular prophylaxis when first seen at the HTC; the prophylactic regimen was modified for 22/48 (46%), often because of breakthrough bleeding. Five of 21 patients (24%) for whom data were available discontinued prophylaxis. Three of those five patients (60%) experienced increased bleeding episodes and the other two (40%) subsequently resumed regular prophylactic infusions because of the increased bleeding. Of the 77 patients not initially receiving prophylaxis for whom data were available, prophylaxis was started or resumed in all. The prophylactic regimen was modified in 57/77 patients (74%) at some point during treatment, often because of breakthrough bleeding. Of the 55 patients whose prophylactic regimens were modified for whom data were available, 22 (40%) discontinued prophylaxis. Thirteen of 20 patients (65%) for whom data were available experienced an increase in bleeding episodes and 7/18 patients (39%) who had discontinued prophylaxis and for whom data were available subsequently resumed regular prophylactic infusions because of bleeding. These findings suggest that prophylaxis prevents bleeding in adults with severe haemophilia A and that discontinuation of the prophylactic regimen is associated with increased bleeding events.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19493018     DOI: 10.1111/j.1365-2516.2009.02036.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  16 in total

1.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

2.  Prophylaxis for adults with haemophilia: towards a personalised approach?

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

Review 3.  New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.

Authors:  Margaret V Ragni
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

4.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

5.  Prophylaxis in haemophilia should be life-long.

Authors:  Mike Makris
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

6.  Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.

Authors:  Joseph Neumeyer; Ruei-Zeng Lin; Kai Wang; Xuechong Hong; Tien Hua; Stacy E Croteau; Ellis J Neufeld; Juan M Melero-Martin
Journal:  Blood Adv       Date:  2019-12-23

7.  Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.

Authors:  M V Ragni; J G Yabes; P F Fogarty; N C Josephson; C M Kessler; A T Neff; L Raffini; K Brummel-Ziedins; C G Moore
Journal:  Haemophilia       Date:  2016-12-11       Impact factor: 4.287

8.  [Treatment of haemophilia in Austria].

Authors:  Ingrid Pabinger; Max Heistinger; Wolfgang Muntean; Sylvia-Elisabeth Reitter-Pfoertner; Sabine Rosenlechner; Thomas Schindl; Gerhard Schuster; Werner Streif; Katharina Thom; Christoph Male
Journal:  Wien Klin Wochenschr       Date:  2015-11-02       Impact factor: 1.704

9.  Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia.

Authors:  Jez Fabes; Susan J Brunskill; Nicola Curry; Carolyn Doree; Simon J Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2018-12-24

Review 10.  Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.

Authors:  Erik Berntorp; Gerald Spotts; Lisa Patrone; Bruce M Ewenstein
Journal:  Biologics       Date:  2014-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.